Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

Bioengineers, immunologists and clinicians collaborate to explore a new approach to fighting cancer.

Thierry Diagana and Jonathan Spector from the Novartis Institute for Tropical Diseases (NITD) discuss learnings about their work in Neglected Tropical Diseases (NTDs) and share insights into the factors, which could lead to a resurgence of these diseases.

A strong background in biological research prepared Daniel Rooks for his role in shaping the early clinical development of new medicines

These stories offer a glimpse into the lives of people touched by a new era of medicine.

Read how NIBR and Dana-Farber scientists aim to expand immunotherapy options for patients